- Report
- July 2025
Global
From €4439EUR$4,900USD£3,826GBP
- Report
- April 2025
- 250 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- April 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- April 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- January 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- July 2025
- 142 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- May 2025
- 143 Pages
Global
From €2717EUR$2,999USD£2,342GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2718EUR$3,000USD£2,343GBP
- Report
- August 2024
- 135 Pages
Global
From €2863EUR$3,160USD£2,467GBP
€3578EUR$3,950USD£3,084GBP
- Report
- October 2020
- 222 Pages
Global
From €2446EUR$2,700USD£2,108GBP
€2718EUR$3,000USD£2,343GBP
- Report
- March 2018
- 255 Pages
Global
From €2120EUR$2,340USD£1,827GBP
€2355EUR$2,600USD£2,030GBP
- Report
- November 2022
- 200 Pages
Global
From €5390EUR$5,950USD£4,646GBP
- Report
- May 2024
- 138 Pages
Global
From €5887EUR$6,499USD£5,075GBP
- Report
- May 2024
- 200 Pages
Global
From €3759EUR$4,150USD£3,240GBP
- Report
- April 2023
- 500 Pages
Global
From €3397EUR$3,750USD£2,928GBP
- Report
- January 2024
- 129 Pages
United States
€3442EUR$3,800USD£2,967GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2718EUR$3,000USD£2,343GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9059EUR$10,000USD£7,808GBP
- Report
- June 2024
- 92 Pages
Global
From €3500EUR$4,139USD£3,122GBP

Sipuleucel-T is a type of immunotherapy drug used to treat prostate cancer. It is a personalized cellular therapy, meaning it is made from a patient's own immune cells. The drug works by stimulating the patient's immune system to recognize and attack prostate cancer cells. It is administered through a series of three intravenous infusions over the course of several weeks.
Sipuleucel-T is approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is the only FDA-approved immunotherapy for prostate cancer.
The market for Sipuleucel-T is relatively small, as it is only approved for a specific type of prostate cancer. However, it is an important treatment option for patients with this type of cancer.
Companies in the Sipuleucel-T market include Dendreon Corporation, which manufactures the drug, as well as other pharmaceutical companies that market and distribute it. Show Less Read more